Publication:
Comprehensive Analysis of Nivolumab, A Therapeutic Anti-Pd-1 Monoclonal Antibody: Impact of Handling and Stress.

dc.contributor.authorTorrente-Lopez, Anabel
dc.contributor.authorHermosilla, Jesus
dc.contributor.authorSalmeron-Garcia, Antonio
dc.contributor.authorCabeza, Jose
dc.contributor.authorNavas, Natalia
dc.contributor.funderI+D+i—Junta de Andalucía, Spain
dc.contributor.funderUniversidad de Granada, Proyectos I+D+i del Programa Operativo FEDER Andalucía 2020
dc.contributor.funderEuropean Regional Development Funds.
dc.date.accessioned2023-05-03T14:20:53Z
dc.date.available2023-05-03T14:20:53Z
dc.date.issued2022-03-17
dc.description.abstractNivolumab, formulated in the medicine Opdivo® (10 mg/mL), is a therapeutic monoclonal antibody (mAb) used in the treatment of different types of cancer. Currently, there is insufficient knowledge about the behaviour of this protein with regards to the risk associated with its routine handling or unintentional mishandling, or when subjected to stress conditions in hospitals. These conditions can be simulated in forced degradation studies, which provide an in-depth understanding of the biophysical and biochemical properties of mAbs. In this study, we carried out a physicochemical and functional characterisation of nivolumab, which was subjected to various stress conditions: heat, freeze/thaw cycles, agitation, light exposure and high hypertonic solution. We used a wide range of analytical techniques: Far-UV CD, IT-FS, DLS, SE/UHPLC(UV)-[Native]MS, and ELISA. The results show that exposure to light was the stress test with the greatest impact on the samples, revelling the formation of non-natural dimers and a different isoform profile. In addition, nivolumab (Opdivo®) demonstrated stability up to 60 °C (1 h). As regards functionality all the nivolumab (Opdivo®) stressed samples were found to be stable except for those subjected to light and agitation, and to a lesser extent, those subjected to FTC 5 and NaCl stresses.
dc.description.versionSi
dc.identifier.citationTorrente-López A, Hermosilla J, Salmerón-García A, Cabeza J, Navas N. Comprehensive Analysis of Nivolumab, A Therapeutic Anti-Pd-1 Monoclonal Antibody: Impact of Handling and Stress. Pharmaceutics. 2022 Mar 23;14(4):692
dc.identifier.doi10.3390/pharmaceutics14040692
dc.identifier.issn1999-4923
dc.identifier.pmcPMC9025134
dc.identifier.pmid35456527
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025134/pdf
dc.identifier.unpaywallURLhttps://www.mdpi.com/1999-4923/14/4/692/pdf?version=1648033999
dc.identifier.urihttp://hdl.handle.net/10668/21547
dc.issue.number4
dc.journal.titlePharmaceutics
dc.journal.titleabbreviationPharmaceutics
dc.language.isoen
dc.organizationHospital Universitario San Cecilio
dc.organizationHospital Universitario San Cecilio
dc.organizationInstituto de Investigación Biosanitaria de Granada (ibs.GRANADA)
dc.page.number22
dc.provenanceRealizada la curación de contenido 08/08/2024
dc.publisherMDPI AG
dc.pubmedtypeJournal Article
dc.relation.projectIDP20-01029
dc.relation.projectIDB-FQM-308-UGR20
dc.relation.publisherversionhttps://www.mdpi.com/resolver?pii=pharmaceutics14040692
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectUHPLC-MS
dc.subjectcomprehensive analytical characterisation
dc.subjectforced degradation
dc.subjectisoform profile
dc.subjectnivolumab
dc.subject.decsAnticuerpos monoclonales
dc.subject.decsCloruro de sodio
dc.subject.decsCromatografía líquida de alta presión
dc.subject.decsEnsayo de inmunoadsorción enzimática
dc.subject.decsHospitales
dc.subject.decsIsoformas de proteínas
dc.subject.decsNeoplasias
dc.subject.decsNivolumab
dc.subject.decsPrueba de esfuerzo
dc.subject.meshNivolumab
dc.subject.meshAntibodies, Monoclonal
dc.subject.meshSodium Chloride
dc.subject.meshChromatography, High Pressure Liquid
dc.subject.meshExercise Test
dc.subject.meshNeoplasms
dc.subject.meshProtein Isoforms
dc.subject.meshEnzyme-Linked Immunosorbent Assay
dc.subject.meshHospitals
dc.titleComprehensive Analysis of Nivolumab, A Therapeutic Anti-Pd-1 Monoclonal Antibody: Impact of Handling and Stress.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number14
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
PMC9025134.pdf
Size:
2.42 MB
Format:
Adobe Portable Document Format
Loading...
Thumbnail Image
Name:
Torrente_ComprehensiveAnalysis_MaterialSuplementario.pdf
Size:
622.74 KB
Format:
Adobe Portable Document Format